resistance to oncogene-targeted therapies
Published 7 years ago • 94 plays • Length 1:10:56Download video MP4
Download video MP3
Similar videos
-
1:08:39
ecological interactions drive evolution of targeted therapy resistance in cancer
-
1:01:07
development of first-in-class inhibitors of oncogenic chd1l for the treatment of colorectal cancer.
-
1:30
overcoming acquired resistance to targeted therapy in colorectal cancer
-
59:37
what will it take to cure cancer? historical context and future directions in cancer medicine
-
26:54
what is acquired resistance to targeted therapy, and why does it occur?
-
3:48
mechanisms of resistance to upfront egfr-targeted therapy
-
1:17:02
resistance to targeted and immunotherapy; what happens next - live recording - september 20, 2022
-
58:33
cancer center symposium series 10 oct 2017
-
53:02
landscape of lung cancer management in 2020
-
49:28
met signaling in nsclc: challenges and opportunities for biomarker development and drug discovery
-
1:33
acquired resistance to anti-egfr therapy in colorectal cancer
-
2:04
acquired resistance to osimertinib in t790m-positive nsclc
-
3:07
third generation egfr tkis for acquired resistance
-
4:28
understanding oncogene-driven lung cancer: targeted therapy advances and challenges
-
52:10
cancer center symposium 11 6 18
-
1:54
targeted therapy patient’s lung cancer care team inspires her to become a nurse
-
2:11
the challenges of drug resistance with targetted cancer therapies
-
3:43
improving access to beneficial clinical trials
-
26:08
resistance to targeted therapies - june 19, 2018 - lung cancer living room™